Details:

Publisher's site:
http://dx.doi.org/10.15585/mmwr.rr6602a1
Personal Author:
Grohskopf, Lisa A. ; Sokolow, Leslie Z. ; Broder, Karen R. ; Walter, Emmanuel B. ; Bresee, Joseph S. ; ... More +
Grohskopf, Lisa A. ; Sokolow, Leslie Z. ; Broder, Karen R. ; Walter, Emmanuel B. ; Bresee, Joseph S. ; Fry, Alicia M. ; Jernigan, Daniel B. ; Less -
Corporate Authors:
United States, Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. ;
United States, Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. ; Less -
Description:
This report updates the 2016–17 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines (MMWR Recomm Rep 2016;65[No. RR-5]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used. For the 2017–18 season, quadrivalent and trivalent influenza vaccines will be available. Inactivated influenza vaccines (IIVs) will be available in trivalent (IIV3) and quadrivalent (IIV4) formulations. Recombinant influenza vaccine (RIV) will be available in trivalent (RIV3) and quadrivalent (RIV4) formulations. Live attenuated influenza vaccine (LAIV4) is not recommended for use during the 2017–18 season due to concerns about its effectiveness against (H1N1)pdm09 viruses during the 2013–14 and 2015–16 seasons. Recommendations for different vaccine types and specific populations are discussed. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended product is available. Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 20, 2016; February 22, 2017; and June 21, 2017. New and updated information in this report includes the following: • Vaccine viruses included in the 2017–18 U.S. trivalent influenza vaccines will be an A/Michigan/45/2015 (H1N1)pdm09–like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008–like virus (Victoria lineage). Quadrivalent influenza vaccines will contain these three viruses and an additional influenza B vaccine virus, a B/Phuket/3073/2013–like virus (Yamagata lineage). • Information on recent licensures and labelling changes is discussed, including licensure of Afluria Quadrivalent (IIV4; Seqirus, Parkville, Victoria, Australia); Flublok Quadrivalent (RIV4; Protein Sciences, Meriden, Connecticut); and expansion of the age indication for FluLaval Quadrivalent (IIV4; ID Biomedical Corporation of Quebec, Quebec City, Quebec, Canada), previously licensed for ≥3 years, to ≥6 months. • Pregnant women may receive any licensed, recommended, age-appropriate influenza vaccine. • Afluria (IIV3; Seqirus, Parkville, Victoria, Australia) may be used for persons aged ≥5 years, consistent with Food and Drug Administration–approved labeling. • FluMist Quadrivalent (LAIV4; MedImmune, Gaithersburg, Maryland) should not be used during the 2017–18 season due to concerns about its effectiveness against influenza A(H1N1)pdm09 viruses in the United States during the 2013–14 and 2015–16 influenza seasons. This report focuses on the recommendations for use of vaccines for the prevention and control of influenza during the 2017–18 season in the United States. A Background Document containing further information and a summary of these recommendations are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to licensed influenza vaccines used within Food and Drug Administration–licensed indications, including those licensed after the publication date of this report. Updates and other information are available at CDC’s influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check CDC’s influenza website periodically for additional information. Suggested citation for this article: Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season. MMWR Recomm Rep 2017;66(No. RR-2):1–20. DOI: http://dx.doi.org/10.15585/mmwr.rr6602a1.
Content Notes:
Leslie Z. Sokolow 10/04/2017
Subject:
[+]
Immunization Schedule
Influenza, Human/epidemiology
Influenza, Human/prevention & Control
Influenza A Virus
Influenza A Virus, H1N1 Subtype
Influenza A Virus, H3N2 Subtype
Influenza B Virus
Influenza Vaccine/Recombinant
Influenza Vaccines
Influenza Vaccines/administration & Dosage
Influenza Vaccines/adverse Effects
Influenza Vaccines/Attenuated
Influenza Vaccines/Cell Culture-based Inactivated
Influenza Vaccines/Efficacy & Effectiveness
Influenza Vaccines/Inactivated
Influenza Vaccines/Safety
Vaccines, Attenuated
Vaccines, Inactivated

Series:
MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports ; v. 66, no. RR-2;
Pubmed ID:
28841201
Document Type:
Journal Issue ;
Genre:
Practice Guideline ;
Place as Subject:
United States ;
Collection(s):
Guidelines and Recommendations
Morbidity and Mortality Weekly Report (MMWR)
Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:
[+]
urn:sha256:57e11b3161c78860c1ecece707f35a746719563d1e0b3bb142eed4c656e82f07
File Type:

Supporting Files

• 	ACIP-recs-2017-18-bkgd.pdf	pdf
  	ACIP-recs-2017-18-summary.pdf	pdf

More +